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Context: Long-term follow-up data on cognitive and motor function-
ing in adult patients with congenital hypothyroidism, diagnosed by
neonatal screening, are scarce. Hence, it is still unclear whether the
frequently reported cognitive and motor deficits observed during
childhood persist in adulthood.
Objective: The objective of this study was to examine cognitive and
motor functioning in young adults with congenital hypothyroidism,
born in the first 2 yr after the introduction of the Dutch neonatal
screening program.
Design/Setting/Patients: Seventy patients were tested (mean age,
21.5 yr); 49 of them were previously tested at 9.5 yr. The median age
at the start of treatment was 28 d (range, 4–293 d). Congenital
hypothyroidismwas classified as severe, moderate, ormild, according
to pretreatment T4 concentrations.
Main OutcomeMeasurement: The main outcomemeasurement was
the influence of the severity of congenital hypothyroidism and age at
which T4 supplementation was started on cognitive andmotor outcome.
Results: Patients, particularly those with severe congenital hypo-
thyroidism, had significantly higher (i.e. worse) motor scores (total
score, 7.8; ball skills, 2.0; balance, 4.1) compared with controls (total
score, 3.2; ball skills, 0.7; balance, 1.1), and lower full-scale (95.8),
verbal (96.4), and performance (95.6) intelligence quotient (IQ) scores
than the normal population. No significant change in IQ from child-
hood to adulthood was found, and for the majority of patients, motor
score classification remained the same. The severity of congenital
hypothyroidism, but not the starting day of treatment, was correlated
with IQ and motor scores.
Conclusions: It is concluded that the severity of congenital hypo-
thyroidism, but not the timing of treatment initiation, is an important
factor determining long-term cognitive and motor outcome. Clearly,
detrimental effects on developmental outcome in patients with con-
genital hypothyroidismpersist over time. (JClinEndocrinolMetab
91: 418–424, 2006)
THYROID HORMONE PLAYS an essential role in braindevelopment during pre- and postnatal life (1). Pre-
natally, the thyroid hormone state is dependent onmaternal-
fetal thyroid hormone transfer and fetal thyroid hormone
production starting from the second trimester onward. Con-
genital hypothyroidism (CH), which implies a total or partial
inability to produce thyroid hormone, is notorious because
of the serious life-long cognitive and motor deficits seen
before the advent of mass CH-screening programs (2, 3). The
influence of impaired thyroid hormone production during
the fetal phase on brain function in later life is largely un-
known. Although it is clear that shortening the postnatal
phase of hypothyroidism is highly effective in eradicating
serious impairments, there is ample evidence that CH
patients diagnosed by neonatal screening are still vulner-
able to persistent cognitive and motor sequela (4). The
magnitude of the deficits is shown to be dependent on the
severity of CH, the timing of T4 treatment initiation, and the
adequacy of treatment (5–9). In an earlier study we showed
that Dutch patientswith CHborn in 1981 and 1982 and tested
at 7.5 and 9.5 yr of age had motor problems and borderline
intelligence scores, especially those with severe neonatal
hypothyroidism (5).
Almost all outcome studies in CH only report data until
late childhood. Consequently, it is not clear whether the
cognitive andmotor problems seen during childhood persist
into adulthood. To date, only one study has reported the
long-term outcome in (young) adult patients with CH (10).
The present study followed an approach in which long-term
cognitive and motor outcome was assessed in young adult
patientswith early-treatedCHborn in 1981 and 1982. Outcome
was analyzed in relation to the severity of CH as well as treat-
ment variables. Furthermore, outcome obtained at an adult age
was related to childhood results from the same individuals (5).
Patients and Methods
Screening method and treatment strategy
The Dutch neonatal CH screening method is primarily based on the
measurement of T4. T4, expressed as an sd score, is compared with the
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Abbreviations: CH, Congenital hypothyroidism; IQ, intelligence quo-
tient; MABC, movement assessment battery for children; TOMI, test of
motor impairment.
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day’s mean. In the early 1980s, sampling was performed between 7 and
14d after birth. If T4was0.8 sd or less, TSHwas additionallymeasured.
If T4 was 3.0 sd or less or TSH was 50 U/ml or more, children were
referred immediately to a pediatrician for diagnostic evaluation. Chil-
dren with a borderline result (3.0  T4 2.1 sd, or 25  TSH 50
U/ml) underwent a second heel puncture and were referred if the
result was again borderline or abnormal. The diagnosis of CH and its
etiological classification were based upon initial presentation, thyroid
function determinants, and thyroid imaging.
In the early 1980s the national guideline for treatment was to start
with one of two schemes. In scheme 1, patients started with T3 supple-
mentation. After 1 wk, T4 was added (4 g/kgd), with a gradual in-
crease to 8–10 g/kgd after 2 wk. With the start of T4 supplementation
the T3 dose was gradually diminished and was stopped after 3 wk. In
scheme 2, patients started with T4 (6 g/kgd), which was increased to
8–10 g/kgd after 1 wk. Thereafter, T4 supplementation doses were
adjusted based on thyroid hormone determinants, measured during
regular out-patient visits, according to international guidelines.
Patients at 21.5 yr of age
The complete cohort of CHpatients born in TheNetherlands between
1981 and 1982 consisted of 136 patients (Table 1). Medical data for these
patients were available in the Academic Medical Center because of
previous studies (5, 11). From the original cohort, four patients had died,
and three hadmoved abroad; five had severe mental retardation related
to chromosomal abnormalities (n  4) or unclassified syndrome with
deafness (n  1; Table 1, nonparticipants, not suitable). In 2001, at the
start of this study, the remaining 124 patients were contacted via their
physicians and asked to participate. A total of 82 patients (66%) gave
their written informed consent; their initial thyroid hormone concen-
trations and treatment modality were recorded. Of this group, 12 pa-
tients were excluded from the study because of central CH (n  1; all
other patients had thyroidal CH), exceptionally late (i.e. 4 yr of age)
start of treatment (n  5), discontinuation of treatment at a young age
(n  4), treatment was never initiated (n  1), or the patient was
unwilling to complete the assessments (n  1; Table 1, nonparticipants,
not suitable).
The remaining 70 patients (Table 1, participants at 21.5 yr), 51% of the
original cohort, were classified into subgroups according to arbitrarily
chosen cut-off levels for severity of postnatal hypothyroidism: severe
CH: initial T4, less than 2.3 g/dl (30 nmol/liter); moderate CH: 2.3
or less than initial T4 less than 4.7 g/dl (30 initial T460 nmol/liter);
or mild CH: initial T4 4.7 g/dl or more (60 nmol/liter). The T4
reference range in children aged 2–6 wk is 6.5–16.3 g/dl (84–210
nmol/liter) (12). The subgroups severe CH and moderate CH were
further classified according to starting day of T4 treatment: early (age,
27 d) or late (age, 27 d) and initial treatment protocol.
The study protocol was approved by the institutional review board
of the Academic Medical Center.
Assessments at 21.5 yr of age
Cognitive and motor assessments were carried out in the 70 partic-
ipating patients at the Academic Medical Center in Amsterdam (except
for four patients who were tested in their local hospitals) by the same
psychologist, whowas blinded for the patients’ medical details. Patients
were tested at a mean age of 21.5 yr (range, 21.0–22.3 yr). To ascertain
that patients were euthyroid (i.e. TSH, 0.4–4.0 U/ml) at the time of
testing, the most recent measurement of thyroid function before the
psychological assessments was evaluated. In those patients with plasma
TSH concentrations outside the reference range, the T4 dose was ad-
justed. This resulted in dose adjustments for 25 patients; in one patient
treatment compliance was optimized.
Cognitive assessments
Intelligence was tested with the Dutch version of the Wechsler Adult
Intelligence Scale III (13).With the subjects’ performances on 11 subtests,
three intelligence quotients were derived: full-scale intelligence quotient
(IQ), verbal IQ, and performance IQ. In the normal population, each IQ
score has a mean of 100 and an sd of 15.
Motor assessments
Motor skills were assessedwith themovement assessment battery for
children (MABC) (14, 15). The MABC is designed for identification of
motor impairments in children. Themanual provides normative data for
children 4–12 yr of age. The test results are expressed in terms of a total
motor impairment scoreMABC (ranging from 0–40), amanual dexterity
score (range, 0–15), a ball skills score (range, 0–10), and a balance score
(range, 0–15); higher scores indicate more motor problems. By conven-
tion, 85% of the normal population have nomotor problems (total motor
impairment score MABC, 9.5), 10% have borderline motor problems
(score, 10–13), and 5% have definite motor problems (score, 13.5).
In the absence of normative data for young adults, the CH patients
were compared with a group of 66 healthy controls (41 females), tested
at a mean age of 21.3 yr. Controls were recruited among students,
hospital employees, and hobby club members. Scores for patients and
controlswere interpreted using the normative data of 12-yr-old children.
Patients and assessments at the age of 9.5 yr
A total of 63 CH patients, 46% of the original cohort of patients born
in 1981–1982 (Table 1, participants at 9.5 yr), and 35 controls were
previously studied at 9.5 yr. IQ was measured with the Wechsler In-
telligence Scale for Children–Revised (16), and motor skills were as-
sessed with the test of motor impairment (TOMI) (17). The TOMI later
evolved into the MABC and contains similar items. The TOMI score
ranges from 0–20. By convention, 85% of the normal population have no
motor problems (TOMI, 4), 10% have borderline motor problems
(TOMI, 4–6), and 5% have definite motor problems (TOMI, 6).
Statistical analysis
One-sample t tests were used to determine whether the IQ scores in
CH patients differed from the norm of 100. Binomial tests were con-
ducted to test whether the percentages of CH patients in the different
severity groupswith an IQ score less than 85 or a totalmotor impairment
scoreMABCgreater than 9.5 differed from the percentages in the normal
population.
Comparisons of IQ andmotor scoresweremade among the following
subgroups: severe vs. moderate vs. mild CH, early vs. late treatment,
initiation with T3 supplementation vs. T4 supplementation, and patients
who participated at 20 yr of age but not at 9.5 yr of age compared with
those who participated at 9.5 yr of age.
TABLE 1. Characteristics of the 1981–1982 cohort
Etiology Total
Nonparticipants Participants
Not suitable Not willing At 21.5 yr At 9.5 yr At 9.5 & 21.5 yr
Thyroid agenesis 36 2 9 25 24 17
Thyroid dysgenesis 59 7 15 37 30 26
Thyroid dyshomonogenesis 17 3 6 8 9 6
Central CH 19 8 11 0 0 0
CH n.o.s. 5 4 1 0 0 0
Total 136 24 42 70 63 49
Six groups are presented; the total group, the group of patients who did not participate divided in patients not suitable or not willing to
participate, the group of patients who did participate at 21.5, 9.5, and at both 9.5 and 21.5 yr of age. For each group, the subdivision according
to etiological classification is given. CH n.o.s., CH not otherwise specified.
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ANOVA was used for group comparisons of continuous variables
(post hoc group comparisons were performed with Bonferroni post hoc
analysis), while 2 tests were used for categorical variables. For variables
where the distributions of scores differed significantly from the normal
distribution, nonparametric tests, such as the Mann-Whitney U tests,
were used.
When multiple analyses were performed with the Mann-Whitney U,
binomial, or 2 tests to compare scores, a correction for multiple testing
was used by considering P  0.01 significant.
It was not necessary to correct for parental educational level, a po-
tential confounder, because parental educational level appeared to be
distributed equally over the subgroups: parental educational level by
severity: 2  0.335; P  0.846; parental educational level by initiation
with T3 or T4: 
2  0.239; P  0.625; parental educational level by early
or late treatment: 2  0.105; P  0.746.
Linear regression models were fitted for IQ and motor scores, with
severity (initial T4 concentration) and starting day of T4 supplementation
as independent variables. In addition, bivariate correlation analyses
between either severity of CH or the starting day of treatment and IQ
andmotor scores were performed. Similarly, bivariate correlations were
calculated between full-scale IQ and total motor impairment score
MABC.
For the longitudinal analysis of IQ scores obtained at 9.5 and 21.5 yr
of age, the paired samples t test (two-tailed) was used. Correlation
analyses (Spearman) were conducted for the TOMI andMABC scores at
the two ages.
Results
Patient characteristics
The baseline characteristics of the participating CH pa-
tients are given in Table 2. Of the 70 patients (55 females,
79%), 35 had severe CH, of whom the majority (21 patients)
had thyroid agenesis. Moderate and mild CH were seen in
16 (23%) and 19 (27%) patients respectively, of whom the
majority had thyroid dysgenesis (9 and 17 patients,
respectively).
Themedian age at start of T4 supplementationwas 28 d for
the total group. In patientswith severe andmoderate CH, the
mean age at start of T4 supplementation was younger than
in those with mild CH (Table 2). In 28 patients, treatment
started with T3 supplementation, and in 39 patients treat-
ment started with T4 supplementation; in three patients, the
initial treatment strategy could not be retrieved with
certainty.
Intellectual and motor outcome at adult age
Mean IQ scores of the total CH group were significantly
lower than the population mean (full-scale IQ: P 0.017; t
2.450; verbal IQ:P 0.042; t2.450; performance IQ:P
0.012; t  2.568; Table 3). Compared with the controls, the
total CH group scored significantly worse on motor scores,
except formanual dexterity (P 0.001; Table 4). Full-scale IQ
and total motor impairment score MABC were significantly
correlated (r  0.442; P  0.001).
Mean full-scale and performance IQ scores differed sig-
nificantly between the severity groups [full-scale IQ:
F(2,67)  3.754; P  0.028; performance IQ: F(2,67)  5.112;
P  0.009; Table 3 and Fig. 1]. Post hoc analysis showed that
the differences in mean full-scale and performance IQs were
significant between severe CH and mild CH (P  0.043 and
P  0.037, respectively). There was also a significant differ-
ence in mean performance IQ between severe CH and mod-
erate CH (P  0.031; Table 3).
Among patients with severe CH, 37% had a full-scale IQ
score less than 85. This percentage was significantly higher
than that in the normal population (P  0.002). In the mod-
erate and mild CH groups, the percentages of children with
a full-scale IQ score less than 85 (19% and 5%, respectively)
were not significantly different from those in the normal
population.
Patients with severe CH performed significantly worse on
the total motor impairment score MABC and manual dex-
terity than patients with moderate CH (P  0.004 and P 
0.007, respectively; Table 4). In the control group, the per-
centage of subjects with a subnormal total motor impairment
score MABC (12% 9.5) was slightly, but not significantly,
lower than that in the normal population (15%9.5). Among
patients with severe CH, 49% had a subnormal total motor
impairment score MABC, which was significantly higher
than the percentage in the normal population or controls (P
0.001). In themoderate andmild CH groups, the percentages
of childrenwith a totalmotor impairment scoreMABCabove
9.5 (14% and 21%, respectively) were not significantly dif-
ferent from those in the normal population or controls.
IQ and motor scores of those patients who started with T3
TABLE 2. Characteristics of the subgroups with different severities of CH
Severe CH Moderate CH Mild CH
No. of patients (male:female) 35 (7:28) 16 (3:13) 19 (5:14)
Initial T4 in g/dl (95% CI)
a [in nmol/liter (95% CI)] 1.1 (0.9–1.4) 3.4 (3.1–3.7) 7.6 (6.2–8.9)
[14.5 (11.5–17.4)] [43.6 (39.5–47.6)] [97.2 (79.8–114.6)]
Initial TSH in U/ml (95% CI)b 497 (298–696) 496 (336–656) 142 (50–234)
Total defects
Agenesis 21 4 0
Dyshormonogenesis 3 1 0
Partial defects
Dysgenesis 11 9 17
Dyshormonogenesis 0 2 2
Age at start of T4 supplementation in d (range) 27 (8–47) 27 (4–47)
c 74 (18–293)
T4 and TSH concentrations are expressed as the mean, with the 95% confidence interval (CI) in brackets. For the etiology subgroups the
number of patients is presented. The age at the start of treatment is presented as the mean, with the range in parentheses.
a Reference range for T4 in children aged 2–6 wk, 6.5–16.3 g/dl (84–210 nmol/liter) (12).
b Reference range for TSH in children aged 2–6 wk, 1.7–9.1 U/ml (12).
c One patient, in whom T4 supplementation was started at the age of 4 d, was already diagnosed before CH screening because of familial
CH.
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supplementation did not differ significantly from those who
started with T4 supplementation, nor were the scores differ-
ent for patients in whom treatment was initiated before or
after the age of 27 d.
In a bivariate correlation analysis, the initial T4 concen-
tration appeared to be associatedwith full-scale IQ (r 0.278;
P 0.020), performance IQ (r 0.330; P 0.005), total motor
impairment score MABC (r  0.337; P  0.005), ball skills
(r0.299; P 0.013), and balance (r0.278; P 0.021).
Correlation analyses showed no correlation between starting
day and IQ or motor scores.
In a multiple regression analysis with severity of CH and
starting day of T4 supplementation as independent variables,
the severity of CH appeared to be a significant predictor of
full-scale IQ (P  0.022), performance IQ (P  0.002), and
total motor impairment scoreMABC (P 0.023); the starting
day of treatment did not predict IQ or motor scores (Table 5).
Intellectual and motor outcome: longitudinal assessment
The IQ scores of the 49 patients tested at 9.5 as well as 21.5
yr are shown in Table 6. The paired samples t test showed no
significant differences in IQ scores at 9.5 and 21.5 yr of age
and a significant correlation among full-scale, verbal and
performance IQ scores at 9.5 and 21.5 yr (r 0.799, P 0.001;
r  0.820, P  0.001; r  0.678; P  0.001, respectively).
There was a significant correlation between motor scores
at 9.5 and 21.5 yr: total motor impairment score MABC (r 
0.339; P 0.017), ball skills (r 0.316; P 0.025), and balance
(r  0.431; P  0.002). For the majority of patients, the clas-
sification of the total motor impairment scores at both ages
were concordant normal (45%) or abnormal (18%). However,
in 36%of patients, totalmotor impairment scores at both ages
were discordant (14% from subnormal at TOMI to normal at
MABC, 22% from normal at TOMI to subnormal at MABC).
IQ and motor scores at 21.5 yr for those patients who did
and those who did not participate at 9.5 yr of age did not
differ significantly.
Discussion
The aim of neonatal screening is to prevent cerebral dam-
age due to lack of thyroid hormone by enabling early and
adequate T4 supplementation.However,we foundpersistent
cognitive and motor deficits in young adults with CH born
in the first 2 yr after the nationwide introduction of screening.
Cognitive deficits were observed in both verbal and perfor-
mance domains, and motor deficits were found in balance,
fine motor, as well as ball skills. Deficits were most pro-
nounced in patients with severe CH and were comparable to
those measured during childhood.
Although several studies have shown subnormal cogni-
tive and motor development during childhood (4, 5, 7, 18),
our study is only the second one reporting on the persistence
of these deficits into adulthood (10). Both studies are com-
parable with regard to the number of participating patients
and the timing of initiation of treatment, but there are two
major differences in the design. In our study, comparisons
were made between severity subgroups and between CH
patients and the normal population, whereas in the study of
Oerbeck et al. (10), the total CH group was compared with
siblings, and no differentiation in severity was made. Oer-
beck et al. (10) found that onlymotor outcome correlatedwith
the severity of CH. We found that also IQ scores correlated
with the severity of CH.
The other major difference in the design is that we con-
sidered euthyroidism at the time of testing an essential con-
dition for each individual patient. Therefore, we verified in
all patients that, before the cognitive andmotor assessments,
plasma TSH concentrations were within the reference range.
TABLE 3. IQ scores of the CH patients at 21.5 yr of age
Full-scale IQ Verbal IQ Performance IQ
Severe CH (n  35) 91.3 (86.3–96.3)a 92.9 (88.1–97.8) 90.4 (85.2–95.6)b
Moderate CH (n  16) 99.1 (91.1–107.1) 97.8 (89.2–106.3) 101.3 (94.8–107.7)
Mild CH (n  19) 101.3 (95.7–106.9) 101.8 (96.1–107.5) 100.4 (94.7–106.1)
Total CH (n  70) 95.8 (92.3–99.2)c 96.4 (93.0–99.9)d 95.6 (92.3–99.2)e
IQ scores (expressed as the mean with confidence interval in parentheses) are presented for the total CH group and the severity subgroups.
a P  0.043 vs. mild CH.
b P  0.031 vs. moderate CH; P  0.037 vs. mild CH.
c P  0.017 (t  2.450) vs. normal population.
d P  0.042 (t  2.077) vs. normal population.
e P  0.012 (t  2.568) vs. normal population.
TABLE 4. Motor scores of the CH patients at 21.5 yr of age
Total motor impairment score MABC Manual dexterity score Ball skills score Balance score
Severe CH (n  35) 9.8 (7.6–11.9)a 2.1 (1.4–2.8)b 2.6 (1.8–3.4) 5.1 (3.6–6.6)
Moderate CH (n  16) 4.3 (2.1–6.5) 0.5 (0.0–0.9) 1.5 (0.3–2.6) 2.4 (1.1–3.7)
Mild CH (n  19) 6.7 (3.5–9.9) 1.8 (0.3–3.4) 1.4 (0.6–2.2) 3.4 (1.6–5.3)
Total CH (n  70) 7.8 (6.3–9.3)c 1.7 (1.1–2.3) 2.0 (1.5–2.5)c 4.1 (3.1–5.0)c
Controls (n  66) 3.2 (2.3–4.2) 1.4 (0.9–1.8) 0.7 (0.4–1.1) 1.1 (0.6–1.7)
Motor scores (expressed as the mean with confidence interval in parentheses) are presented for the total CH group, the severity subgroups,
and the controls.
a P  0.004 vs. moderate CH.
b P  0.007 vs. moderate CH.
c P  0.001 vs. control group.
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In Oerbeck’s study (10), however, the mean TSH concentra-
tion at the time of testing was 12.2 U/ml. The supposedly
suboptimal treatment potentially influenced the patients’
cognitive functioning (i.e. attention, speed of processing, etc.)
(19, 20), which impedes judgments on the effect of severity
of hypothyroidism on outcome.
Because important steps in brain development take place
from early gestation until several years after birth, outcome
determinants of CH patients should be correlated to both
pre- and early postnatal thyroid hormone concentrations.
According to term cord plasma T4 concentrations, the pre-
natal thyroid hormone state in fetuses without (functioning)
thyroid tissue is comparable to the postnatal thyroid hor-
mone state in neonates with moderate CH (21). This must be
the effect of a substantial, but limited, maternal-fetal transfer
of T4. It is likely that this maternal contribution to the fetal
thyroid hormone state is a major factor in protecting brain
development, but it is not known whether it is always suf-
ficient to completely preserve prenatal brain development.
When, in particular in patients with severe CH, T4 concen-
trations rapidly decline after birth, this is undoubtedly a
dangerous condition with respect to thyroid hormone-de-
pendent brain development. Neonatal screening is only ca-
pable of shortening the period of postnatal thyroid hormone
deficiency; once T4 supplementation is started, plasma free
T4 concentrations increase rapidly (22).
Only in our patients diagnosed with severe CH (pretreat-
ment T4 concentrations, 2.3 g/dl) were significant cog-
nitive and motor deficits found. This underlines that the
severity of CH is an important factor determining cognitive
FIG. 1. Full-scale IQ, verbal IQ, and performance IQ scores of the CH
patients at 21.5 yr of age. The box plot shows the full-scale IQ, verbal
IQ, and performance IQ scores of the CH severity subgroups. The box
incorporates 50% of all observations, the dash represents the median
IQ score, and the whiskers represent the highest and lowest scores.
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and motor outcomes (4, 6, 8, 18, 23). The question is whether
earlier initiated postnatal T4 supplementation had been able
to prevent the observed damage. In our study, we could not
find any relation between the day treatment was initiated
and IQ ormotor scores, nor didwe findwithin the severe CH
group a beneficial effect of early treatment initiation. This
might be influenced by the fact that treatment initiation was
strongly correlated with the severity of CH or by too little
variation in the day of the start of treatment.
An important consideration is that the patients in our
studywere among the first Dutch patients screened andwere
treated relatively late (mean, 27 d for severe and moderate
CH; 74 d for mild CH), with lower T4 doses than have been
advised in more recent years (24). It is possible that the time
frame for early and adequate treatment to prevent cerebral
damage was before the age at which treatment was initiated
in these patients. Indeed, some studies indicate that even
patients with severe CH, assessed in the first 3 yr of life, had
normal cognitive and motor outcomes if treatment started
early and with high initial T4 doses (25, 26). However, others
did not find a beneficial effect on developmental outcome of
higher (6 g/kgd) compared with lower (6 g/kgd)
initial T4 doses, in patients treated before the age of 3wk (27),
nor couldwe demonstrate in a previous study that variations
in the initial T4 dose influenced the time needed to reach a
plasma free T4 concentration within the reference range (22).
Furthermore, it still needs to be established whether im-
provements in IQ due to optimized timing and/or dose of
treatment lead to improved well-being without detrimental
effects on behavior or social emotional development (28, 29).
Several investigators have reported that the adequacy of
long-term T4 supplementation influences outcome (25, 30,
31). Yet, this variable was not studied explicitly in the Dutch
cohort, because, in our opinion, treatment adequacy is dif-
ficult to assess by integrating the numerous plasma TSH and
free T4 concentrations from infancy to adulthood. As in
healthy people, concentrations in well-treated patients may
vary considerable (32), and mean values completely disre-
gard intraindividual fluctuations and interindividual varia-
tions. The durations of phases of inadequate treatment (es-
pecially lack of compliance) cannot be established in
retrospect. Besides, treatment of CH patients is remarkably
uniform regardless of severity. All studied patients were
treated according to criteria of good clinical practice by pe-
diatricianswho rely on (inter)national guidelines (preserving
euthyroidism primarily by maintaining plasma TSH concen-
trations within the reference range with regular T4 dose
adjustments). Therefore, we had no reason to assume group
differences in long-term treatment adequacy, including com-
pliance. Patients with moderate or mild CH had IQ scores
indistinguishable from those of the normal population, in-
dicating implicitly that even if these patients had experienced
phases of insufficient treatment, these had no consequences
for intellectual outcome at adult age. This makes it unlikely
that the IQ deficits observed in patients with severe CH had
anything to do with long-term treatment insufficiency.
The use of the MABC in this study requires some com-
ment. This test is developed to detect motor problems in
children; consequently, normative data for adults are not
available. Nevertheless, we applied this test to detect mo-
tor problems in adults with CH by using norms of 12-yr-
old children. This might have resulted in an underesti-
mation of motor problems in our patient group. Indeed,
the percentage in the adult control groupwith a subnormal
motor score (12%) was slightly, but not significantly, lower
than that in the general population (15% by convention).
However, even with a potential underestimation, the CH
group had substantially more motor problems than the
control group.
In conclusion, this study has shown that cognitive and
motor deficits in CH patients, who started treatment at a
median age of 28 d after birth, persist into adulthood. Mildly
and moderately affected patients have a fair prognosis,
whereas severely affected CH patients continue to experi-
ence IQ and motor problems in later life. Cognitive and
motor outcomes could not be related to the age at which T4
treatment was initiated. Apparently the postnatal treatment
strategyused in TheNetherlands in the early eightieswas not
capable of abolishing all negative effects of severe congenital
hypothyroidism.
Regarding the directions for future research, it is impor-
tant to move beyond the mere task of establishing levels of
cognitive and motor functioning and also investigate the
long-term social emotional and behavioral consequences of
early-treated CH.
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TABLE 6. IQ scores of the CH patients tested at 9.5 and 21.5 yr of age
Severe CH (n  22) Moderate CH (n  14) Mild CH (n  13)
9.5 yr 21.5 yr 9.5 yr 21.5 yr 9.5 yr 21.5 yr
Full-scale IQ 91.1 (85.2–97.0) 90.6 (84.2–97.1) 99.7 (91.9–107.5) 100.2 (91.7–108.8) 101.9 (91.8–112.1) 102.5 (96.1–109.0)
Verbal IQ 91.3 (85.3–97.2) 92.8 (86.2–99.4) 96.4 (89.2–103.5) 98.9 (89.4–108.5) 98.5 (90.2–106.8) 102.1 (95.8–108.3)
Performance IQ 92.6 (87.1–98.1) 89.0 (82.3–95.7) 103.9 (95.7–112.0) 102.3 (96.1–108.5) 105.3 (94.0–116.6) 102.7 (96.3–109.1)
IQ scores (expressed as the mean with confidence interval in parentheses) are given for the 49 patients tested at 9.5 and 21.5 yr of age.
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